← Leaderboards
Brian C Betts
H. Lee Moffitt Cancer Ctr & Res Inst
$4,001,397
Attributed
$5,082,670
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $741.6K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,082,670 · 3
By mechanism
R01$4,391,362 · 2
K08$691,308 · 1
Top collaborators
- Marco L. Davila3 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- William D Cress$7,111,958
- Stephanie L. Schmit$6,323,663
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsAllogenicProphylactic TreatmentT-LymphocyteClinical TrialsAcute Graft Versus Host DiseasePreventTransplantationInnovationLifeRegulatory T-LymphocyteGraft Vs Leukemia EffectFutureInvestigationInterleukin-6PhosphorylationMortalityInhibitor/AntagonistNovel StrategiesJak2 GeneDesignMediatingComplicationPathway Interactions
Grant awards (14)
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation$711,892
R01 · FY2025 · HL · contact PI
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation$709,029
R01 · FY2024 · HL · contact PI
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneic hematopoietic cell transplantation$741,625
R01 · FY2023 · HL · contact PI
Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVL$409,210
R01 · FY2020 · HL · contact PI
Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVL$400,586
R01 · FY2019 · HL · contact PI
Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVL$427,457
R01 · FY2018 · HL · contact PI
Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVL$1
R01 · FY2018 · HL · contact PI
Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVL$495,781
R01 · FY2017 · HL · contact PI
JAK2_STAT3 as a therapeutic target and marker of graft-versus-host disease$156,924
K08 · FY2017 · HL · contact PI
Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVL$495,781
R01 · FY2016 · HL · contact PI
JAK2_STAT3 as a therapeutic target and marker of graft-versus-host disease$156,924
K08 · FY2016 · HL · contact PI
JAK2_STAT3 as a therapeutic target and marker of graft-versus-host disease$125,820
K08 · FY2015 · HL · contact PI
JAK2_STAT3 as a therapeutic target and marker of graft-versus-host disease$125,820
K08 · FY2014 · HL · contact PI
JAK2_STAT3 as a therapeutic target and marker of graft-versus-host disease$125,820
K08 · FY2013 · HL · contact PI